SEC Tracker
Get the app

Possible new CRSP shares

CRSPDilution

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants.

Shelf room

  • Room today not capped by the baby-shelf rule ($4.1B float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3ASR of Aug 5, 2024: not limited by the baby-shelf rule, because the $4.1B public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3ASR Aug 5, 2024, effective Aug 5, 2024 · public float, as of Jun 30, 2025.

What could become new CRISPR Therapeutics (CRSP) shares: convertible notes, options and RSUs and an ATM program, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

CRSP dilution ladder

Every source of new shares on record, from the filings that created it.

97M outstanding; up to 103.6M fully diluted, +7%

  1. Outstandingas of Oct 30, 2026 (10-Q filed Nov 2) · share count on the cover page
    97M
  2. At-the-market program$592.2M sold10-Q Nov 2, 2026 · equity noteshown in dollars and left out of the share total: no filing states a price to convert it at
    not added
  3. Convertible notesconvert at $76.5610-Q Nov 2, 2026 · equity noteleft out of the share total: no filing states the shares on conversion
    not added
  4. Options and RSUs6.6M options10-Q Nov 2, 2026 · equity note
    +6.6M

Not stated in the filings we read: warrants.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Nov 2, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

97.0M

Feb 2025 to Oct 2026: from 85.8M to 97.0M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.